Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “0.05% VOS, in both eyes (OU) twice a day (BID) over 12 weeks”In the company’s words, NCT04147650 on ClinicalTrials.gov
- Tested for
- Dry Eye Syndrome, Keratoconjunctivitis Sicca
- Main trialPhase 2/3
- “A Multi-Center, Phase 2/3, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Voclosporin Ophthalmic Solution (0.05%, 0.10%, 0.20%) Compared to Vehicle in Subjects with Dry Eye Syndrome.”In the company’s words, NCT04147650 on ClinicalTrials.gov
Other drugs for Dry Eye Syndrome
- LicaminlimabOculis · Phase 2/3
- NipocalimabJohnson & Johnson (Janssen) · Phase 3
- VVN001VivaVision Biotech, Inc · Phase 3
- CAM-101Cambium Bio Limited · Phase 3
- TelitaciceptVor Biopharma · Phase 3
- OT202Ocumension Therapeutics (Shanghai) Co., Ltd · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Completed | 17 Sep 2020 | Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026